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SUMMARY 
Background/Aims: To identify clinical significances of portal vein embolization (PVE) 
prior to major hepatectomy, we examined clinical parameters and outcome after right 
hepatectomy in patients who underwent PVE.  
Methodology: The subjects were 30 patients who underwent PVE (PVE group), and 52 
patients (non-PVE), in whom PVE was considered unnecessary, followed by right 
hepatectomy for hepatobiliary cancer.  
Results: Total hepatic volume after PVE (1068±268 ml) tended to increase compared 
with before PVE (p=0.059). After PVE, the change in hemi-liver volume was 8.9±6.0%. 
Increases in hepatic volume of non-embolized left liver before and at 4 weeks after 
hepatectomy between PVE and non-PVE groups were similar. Changes in hepatic 
volumes before and after PVE were not significantly influenced by background liver 
disease. After PVE, the functional liver volume (419±185 cm3) was significantly lower 
than morphological volume (564±165 cm3) in the embolized liver (p<0.05). Although 
preoperative liver function was worse in PVE group compared with non-PVE, serious 
hepatic complications were rarely observed in PVE group.  
Conclusions: Marked changes in hepatic volume were noted after PVE in patients with 
impaired liver function and those who need large-volume right hepatectomy, especially 
in functional volume, suggesting that PVE is a useful procedure to prevent post-operative 
liver failure. 
KEYWORDS: Right hepatectomy; Portal vein embolization; Liver regeneration; 
Hepatic failure 
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The incidence of posthepatectomy liver failure has markedly decreased in recent 
years following the introduction of adequate preoperative evaluation of hepatic function 
and estimation of resected liver volume, in addition to improvements in perioperative 
management (1,2). However, the risk of posthepatectomy hepatic failure after extensive 
hepatic resection for hilar bile duct carcinoma or hepatocellular carcinoma (HCC) with 
preexisting impaired liver function is still a serious problem (3-5). In patients who 
undergo right hepatectomy or a larger volume of liver resection, the preoperative portal 
vein embolization (PVE) technique, which allows reduction of the size of resected liver 
volume and induces hypertrophy of the remnant liver volume, is a useful option to 
improve outcome after hepatectomy (6-8). By applying PVE, right hepatectomy may be 
possible in some population of patients with liver dysfunction. Interestingly, relative 
hypertrophy of the remnant volume may be obtained even in patients with impaired liver 
function including liver cirrhosis or jaundice in addition to normal liver (9, 10). 
In a previous pilot study, we examined the dynamic changes in morphological and 
functional hepatic volume following PVE by using computed tomography (CT) and 
technetium-99m galactosyl serum albumin (99mTc-GSA) liver scintigraphy (11). The 
purpose of the present study was to clarify the clinical significance of PVE. For this 
purpose, we compared the outcome of patients who underwent preoperative PVE for right 
hepatectomy and those who underwent right hepatectomy without PVE. 
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METHODOLOGY 
Patients 
The subjects were 30 patients who underwent preoperative PVE prior to right 
hepatectomy (PVE group) in the Division of Surgical Oncology, Department of 
Translational Medical Sciences, Nagasaki University Graduate School of Biomedical 
Sciences (NUGSBS) between 1998 and 2006. They included 23 males and 7 females with 
a mean age of 63.410.1 years (SD, range, 39-78 years). Liver diseases included 
hepatocellular carcinoma (n=16), intrahepatic cholangiocarcinoma (n=1), metastatic liver 
carcinoma (n=2), gallbladder carcinoma (n=5) and hilar bile duct carcinoma (n=6). The 
background liver diseases included normal liver function (n=8), chronic viral liver 
diseases (n=16; caused by hepatitis B virus [n=9] or hepatitis C virus [n=7], including 4 
with cirrhosis) and obstructive jaundice (n=6). The control group consisted of 52 patients 
who underwent right hepatectomy without PVE during the same period (non-PVE group), 
in whom the latter procedure was not necessary for the reason described below. They 
included 41 males and 11 females with a mean age of 59.78.4 years (SD, range, 35-77 
years). Liver diseases included hepatocellular carcinoma (n=8), intrahepatic 
cholangiocarcinoma (n=11), metastatic liver carcinoma (n=25), and hilar bile duct 
carcinoma (n=8). The background liver diseases included normal liver function (n=26), 
chronic viral liver diseases (n=20; caused by hepatitis B virus [n=16] or HCV [n=4], but 
no cirrhosis) and obstructive jaundice (n=6). 
 
Indications of PVE and Hepatectomy 
In patients with obstructive jaundice, the biliary drainage was conducted. And the 
hepatic function and operative indication were evaluated at the serum bilirubin level 
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under 2mg/dl. In our hospital, the permitted resected liver volume is determined 
pre-operatively by results of indocyanine green retention rate at 15 minutes (ICGR15) 
using Takasaki’s formula (12). The estimated resected liver volume, excluding tumor 
volume (cm3), is measured by CT volumetry (13). Essentially, the planned hepatectomy is 
performed when the permitted resected volume of the liver is greater than the estimated 
resected volume of the liver. In cases where the permitted resected volume is less than the 
estimated volume, or the estimated volume is more than 65% in patients with normal liver 
and 50% in those with cirrhosis, pre-operative PVE is selected (11, 14). Liver activity at 
15 minutes (LHL15) of 99mTc-GSA scintigraphy or serum hyaluronic acid level was 
used as a reference when evaluating operative indication (15). Functional liver volume 
calculated by 99mTc-GSA scintigraphy before and after PVE was also examined (11,16). 
Hepatectomy was abandoned after laparotomy in 3 patients because of far advanced stage 
of tumors, and these three cases were excluded from further analysis. The parameters 
used for comparisons of the two groups (with and without PVE) were changes in hepatic 
volumes at 14 days after PVE, changes in hepatic volumes at 28 days after hepatectomy, 
and postoperative complications. The study design was approved by the Ethics Review 
Board of our institution and a signed consent for PVE was obtained from each subject. 
The present analysis was a retrospective study. Data were retrieved from both anesthetic 
and patient charts plus the NUGSBS database, for the duration of the initial 
hospitalization following hepatectomy. 
Techniques of PVE 
     Technique of portal vein embolization and evaluation was described as follows. The 
two approaches to the right portal vein were direct catheterization of the ileocolic vein 
(n=15) and percutaneous transhepatic puncture (n=15) (6-8). Substances used for 
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embolization in our series included 1 g of absorbable gelatin sponge powder (Gelfoam®; 
Upjohn, Kalamazoo, MI) and 5,000 units (5 ml) of liquid thrombin (Sankyou Co., Tokyo) 
mixed in the contrast media. These substances were used in PVE conducted between 
1998 and 2004 and, however, could not be used because of off-sale and severe thrombosis 
at our institute since 2005. Between 2005 and 2006, therefore, a mixture of 0.6 g of 
gelatin pieces (Spongel; Astellas Pharma Inc., Tokyo) and 5 ml of lipiodol Ultra-fluid 
(Shering, Berlin) was used to produce PVE. Permanent embolization materials were not 
used in the present series. Embolization was complete when the entire right portal vein 
was completely occluded. At 14 days after PVE, the hepatic volumes of the 
non-embolized hemi-liver and embolized hemi-liver (liver to be resected) were 
reassessed by CT volumetry (8, 13). Surgical resection of the liver was performed at 21 
-28 days after PVE. Postoperative complications occurred in 12 of 30 patients in PVE 
group (40%) patients, and included uncontrolled ascites (defined as massive ascites 
unresponsive to diuretics for more than 2 weeks) in 5 patients; hepatic failure (defined by 
total bilirubin of >3 mg/dl on postoperative day 14) in one. 
 
Statistical Analysis 
All continuous data were expressed as mean  SD. Data for different groups were 
compared using one-way analysis of variance. Chi-square test was used for comparison 
of categorical variables. Differences between groups were analyzed by Fisher’s exact test 
or Scheffé’s multiple comparison test. A two-tailed P value of less than 0.05 was 
considered significant. StatView Software for Windows, version 5.0 (SAS Institute, Inc., 
Cary, NC) was used in all statistical analyses. 
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RESULTS 
Changes of Hepatic Volumes after PVE 
No serious morbidity or mortality was recorded during the 3-week period after PVE. 
For the 30 patients of the PVE group, total hepatic volume, volumes of the right and left 
hemi-livers estimated before PVE were 1027±245 ml, 631±177 ml and 395±147 ml, 
respectively. The ratio of the left liver to total liver was 38.1±8.8%. Total hepatic 
volume after PVE (1068±268 ml) tended to be higher than that before PVE but the 
difference was not significant (p=0.059). After PVE, the volumes of embolized and 
non-embolized livers were 557±185 ml (a decrease of 8.9±6.0%) and 511±150 ml (an 
increase of 8.9±6.0%), respectively. Figure 1 shows changes in hepatic volumes in 
non-embolized liver after PVE and after hepatectomy. The volumes of non-embolized 
left liver were significantly increased during these periods (p<0.05). Increases in hepatic 
volume before and at 4 weeks after hepatectomy between the PVE group and the 
non-PVE group were not significantly different (p=0.89).  
Figure 2 shows changes in hepatic volumes before and after PVE, and after 
hepatectomy in the PVE group. The background liver disease did not significantly 
influence the changes in hepatic volumes during these periods. 
Figure 3 shows changes in hepatic volume calculated by CT volumetry 
(morphological volume) and liver scintigraphy volumetry (functional volume) before and 
after PVE in 11 patients of the PVE group. Morphological (609±185 cm3) and functional 
(628±155 cm3) hepatic volumes of the embolized liver before PVE were not significantly 
different (right liver, open bars, Figure 3). Morphological (354±123 cm3) and functional 
(357±164 cm3) hepatic volumes of the non-embolized liver before PVE were not 
significantly different (left liver, open bars, Figure 3). After PVE, the functional liver 
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volume (419±185 cm3) was significantly lower than morphological volume (564±165 
cm3) in the embolized liver. On the other hand, the functional (477±118 cm3) and 
morphological (481±105 cm3) hepatic volumes in the non-embolized liver were not 
significantly different after PVE. 
 
Patient Outcomes 
In patients undergoing right hepatectomy, none of the patients of the non-PVE group 
had liver cirrhosis and proportion of patients with normal liver in the non-PVE group was 
higher than that of the PVE group (Table 1). The distribution of background liver 
diseases was significantly different between groups (p<0.05). Similarly, the preoperative 
value of ICGR15 in the PVE group was significantly worse than that of the non-PVE 
group (p<0.01). The incidence of postoperative complications was similar between the 
two groups. Serious postoperative complications such as sepsis, disseminated 
intravascular coagulation and hepatic failure were observed in the non-PVE group, but 
rare in the PVE group. In both groups, none of the patients died during hospitalization. 
 
DISCUSSION 
PVE is an established strategy for major hepatectomy in patients with injured liver 
function or patients with bile duct carcinomas in the hepatic hilum (3, 6-10). However, to 
our knowledge, comparison of clinical results between patients undergoing right 
hepatectomy after PVE and patients without PVE has not been reported. In patients who 
underwent PVE, right hepatectomy was risky for postoperative hepatic failure under the 
balance between resected or remnant hepatic volume and functional liver reserve such as 
the parameter of ICGR15 by our criteria (11). By applying PVE, right or extended right 
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hepatectomy could be performed in patients with impaired liver function. We considered 
that clinical results of patients who undergo PVE, compared to patients who undergo 
right hepatectomy without PVE, are important to clarify the clinical significance of PVE. 
We have previously analyzed various issues related to the efficacy and safety of 
preoperative PVE such as relationship with serum hyaluronic acid level, predictive 
parameters for changes in hepatic volumes and evaluation of functional liver volume 
(10,11). The present results and those of other investigators indicate marked changes 
within a short period, in morphological volumes of embolized and non-embolized liver 
after PVE (6-11, 17-19). Before PVE, surgeons may consider the extent of changes in the 
right and left lobes induced by PVE. Our study showed approximately 9% change in 
hepatic volumes between embolized and non-embolized liver. There is concern on 
whether the remnant liver could still regenerate after PVE followed by hepatic resection. 
The present results showed that the volume of remnant liver favorably increased after 
hepatectomy and, therefore, the capacity of regeneration should remain after PVE. 
Although the hepatic volume significantly increased at 2 weeks after PVE, that of the 
non-embolized (remnant) lobe still increased at 4 weeks after hepatectomy in the present 
study. Eventually, the hepatic volume attained after hepatectomy in the PVE group was 
similar to that after hepatectomy of the control non-PVE group. Therefore, the potential 
of regeneration in the non-embolized liver is well preserved regardless of post-PVE 
status.  
Atrophy of the embolized lobe and hypertrophy of non-embolized lobe were also 
observed even in the impaired liver (9, 10, 19). The present results showed that changes in 
hepatic volumes were not significantly different between normal and impaired livers. 
Therefore, PVE can be applied for patients with liver cirrhosis as well. Based on our 
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results and those of others, 9-30% increase in the volume of the non-embolized lobe 
(estimated remnant liver) can be expected in any background liver (7, 11, 18, 20, 21). 
However, the indication for PVE in cirrhotic patients may be based on functional liver 
reserve. Dual embolization of portal vein and hepatic artery at the interval of a few weeks 
is a useful option in such cases (20). We have examined the predictors of changes in 
hepatic volume in patients undergoing PVE and found that alkaline phosphatase level and 
platelet count were associated with changes in hepatic volume (22).  
Recently, measurement of functional hepatic volume in each segment or lobe of the 
liver by 99mTc-GSA scintigraphy has become available and correlation between the 
morphological volume using CT-volumetry and functional volume using RI-volumetry 
has been reported (23-25). In a preliminary study, we examined previously the correlation 
between morphological and functional hepatic volumes after PVE in 5 cases (11). Similar 
to this finding, the decrease in functional hepatic volume in the embolized liver after PVE 
in 11 patients was more than that of morphological volume. Similar to our previous study, 
these changes were not related to background liver disease. Sugai et al. (25) also reported 
no significant increase in functional volume of the non-embolized liver, but they noticed 
marked increase in liver uptake density. Asialoglycoprotein binds specifically to 
hepatocytes via a receptor (26). Decreased counts on scintigraphy might be observed 
specifically in damaged livers. Atrophy of the embolized liver is thought to be due to 
apoptosis and hypertrophy of non-embolized liver may be limited morphologically (27). 
If the 99mTc-GSA scintigraphy results were more reliable as a functional change, the 
safety of major hepatectomy following PVE might be confirmed (6-9, 18-21). This 
finding in the present study might represent a functional shift from embolized liver to 
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non-embolized liver after PVE, which should support the effectiveness and usefulness of 
PVE.  
Postoperative hepatic complications have significantly decreased following the wide 
use of PVE technique in the last decade (6-8, 11, 19-21). However, such complications or 
risk of hepatic failure cannot be completely avoided at this stage (20, 21, 28-31). In the 
present study, hepatic complications were also observed in the PVE group and, however, 
serious hepatic complications including hepatic failure were observed in only one patient 
in the PVE group. Basically, hepatic impairment was more frequent in the PVE group 
compared to the non-PVE group and PVE may help to carry out right hepatectomy in 
patients with impaired liver function. As the purpose of PVE is to avoid hepatic failure 
after major hepatectomy, our results strongly support the clinical usefulness by PVE.  
In conclusion, we have reported changes in hepatic volume, functional hepatic volume 
and outcomes after portal vein embolization in patients scheduled for extensive right 
hepatectomy. The effect of PVE was not different in patients with normal liver and 
impaired liver and further regeneration in the non-embolized liver after hepatectomy was 
noticed. The decrease in functional volume was apparently larger in the embolized right 
liver following PVE compared with morphological volume. Severe hepatic 
complications were avoided in patients with impaired liver who underwent right or 
extended right hepatectomy. Our results highlighted the clinical usefulness of PVE for 
patients undergoing major hepatectomy. 
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FIGURE LEGENDS 
 
Figure 1  Measurement of hepatic volume in the non-embolized lobe at 2 weeks after 
PVE and at 4 weeks after hepatectomy in the PVE group and control group.  
 
Figure 2  Changes in hepatic volume in the non-embolized lobe at 2 weeks after PVE and 
at 4 weeks after hepatectomy in the PVE group.  
 
Figure 3  Changes in morphological and functional hepatic volumes in the embolized and 
non-embolized liver before and after PVE in 11 patients. Data are mean ± SD of 11 
patients. 
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TABLE 1 Comparison of Clinical Status and Outcome after Right Hepatectomy in the 







Background liver    
Normal/Chronic hepatitis/Cirrhosis/Obstructive 
jaundice 
8/12/4/6 26/20/0/6 0.016 
Preoperative liver functions    
Total bilirubin (mg/dl)* 1.3±1.8 1.0±0.3 0.68 
Prothrombin activity (%)* 97±15 93±11 0.57 
Alanine aminotransferase (IU/L)* 65±51 45±49 0.08 
ICGR15 (%)* 16.7±8.6 9.2±6.0 <0.01 
99mTc-GSA (LHL15)* 0.93±0.03 0.93±0.04 0.90 
Postoperative complications 11 (36.7%) 17 (32.7%) 0.76 
Uncontrolled ascites 5 6 0.74 
Bile leakage 2 2  
Intra-abdominal infection 2 3  
Pneumonia 1 1  
Wound infection 1 0  
Sepsis 0 1  
Disseminated intravascular coagulation 0 1  
Hepatic failure(Total bilirubin level>3 mg/dl,>14 
days) 
1 3  
 
*Data are mean±SD 
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